1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On June 24, 2026, Allegiant Travel Company issued $650 million of 7.125% senior secured notes due July 1, 2031, and used part of the proceeds to buy $377.5 million of its 7.25% notes due 2027 tendered in a tender offer. The new notes are secured by substantially all company and guarantor assets except aircraft, aircraft engines and real property, and the company must keep at least $300.0 million of liquidity at each quarter end. Shareholders should note the added secured debt and the restrictive terms, while the filing does not give total debt or cash balances.
$650.0 million of 7.125% notes issued June 24, 2026, maturing July 1, 2031, with cash interest due January 1 and July 1 starting January 1, 2027
$377,534,000 of 7.25% notes due 2027 purchased on June 24, 2026, at total consideration of $1,005.00 per $1,000 principal; $25,465,000 remain and are expected to be redeemed in third quarter 2026
Notes are secured by substantially all assets excluding aircraft, aircraft engines and real property; a $300.0 million minimum liquidity covenant applies, with 2.0% additional interest if breached
Existing 2027 notes indenture amended to remove most restrictive covenants and cut the redemption notice period from 30 days to 3 business days
The FDA approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for thyroid eye disease regardless of disease activity or duration, and the company plans to launch it immediately. The approval is Viridian's first FDA-approved product and first commercial product, a milestone that moves the company from development toward sales.
FDA approval announced June 26, 2026; Lumvoa is the first TED treatment with labeling covering both active and chronic TED
Launch planned immediately; physicians can prescribe Lumvoa tomorrow, per the press release
Lumvoa is given as five intravenous infusions over 12 weeks; infusion reactions reported in about 9% of patients
Conference call and webcast scheduled Monday, June 29, 2026 at 8:00 a.m. ET
Phibro Animal Health said Daniel (Dani) Bendheim will become Chief Executive Officer and President effective July 1, 2026, under a new employment agreement with a $850,000 base salary. He also received a grant of 300,000 performance-based restricted stock units that vest only if the company's 90-day average stock price reaches $70 to $100 by June 30, 2031.
Bendheim's base salary is $850,000 annually, with a target bonus of 50% of base salary.
The 300,000 RSUs vest in 25% increments tied to a 90-day average stock price from $70 to $100 or above, with no vesting below $70.
Severance includes six months of base salary on death or disability and up to 18 months of company-subsidized COBRA coverage on termination without Cause or resignation.
Applied Digital's subsidiary APLD Intermediate HoldCo entered into an incremental agreement that raises the revolving credit commitments under its May 29, 2026 credit agreement to $430.0 million, maturing May 28, 2029. The company also amended its Preferred Equity Purchase Agreement to lift the Series G Convertible Preferred Stock commitment from $1.59 billion to $2.0 billion, adding capacity for future equity issuance to investors.
Secured revolving credit facility increased to $430.0 million, maturing May 28, 2029, with up to $120.0 million more available for a total of $550.0 million
Credit facility priced at Term SOFR plus 2.25% or base rate plus 1.25%, guaranteed by the company and restricted subsidiaries
PEPA Series G Convertible Preferred Stock commitment raised from $1,590,000,000 to $2,000,000,000 under the Sixth Amendment dated June 26, 2026
Fortrea appointed Jason Knoblauch as chief financial officer, effective July 6, 2026, succeeding Jill McConnell, who steps down on that date but will stay with the company for a transition period. The company said the change does not reflect any disagreement with Ms. McConnell over financial reporting, internal controls, or auditing. Fortrea also reiterated its full-year 2026 guidance, which it did not change.
Jason Knoblauch, 45, becomes CFO effective July 6, 2026; he previously was CFO at Clario, from August 2023 to June 2026.
Offer letter dated June 22, 2026 sets a $570,000 base salary, an 85% target bonus, and a $1,250,000 cash inducement paid $500,000 at start and $750,000 after one year.
Planned inducement equity of about $2,300,000 in RSUs and $1,700,000 in PSUs, anticipated in September 2026, capped at 400,000 shares combined.
2026 guidance reiterated: revenues of $2,550 million to $2,650 million and adjusted EBITDA of $190 million to $220 million.
Bristow Group agreed on June 23, 2026 to buy Berry Aviation, a special missions and government aviation provider, for $105 million in cash, subject to adjustments. The company also said it is pursuing a sale of its Norway offshore energy services business, and that the Berry deal would be neutral to its 2025 EBITDA on a pro forma basis with that exit.
Purchase price is $105 million in cash, subject to adjustment for working capital, cash, indebtedness and transaction expenses
Berry Aviation had 2025 total revenues of approximately $108 million and 2025 EBITDA of approximately $12 million, per the investor slides
Closing is expected in the third quarter of 2026 per the press release; the 8-K says the second half of 2026
Bristow intends to fund the deal with cash on hand; the Norway sale timing and structure remain subject to market conditions
Goodyear said Chief Financial Officer Christina Zamarro will step down effective June 30, 2026 and leave the company on July 10 to pursue another opportunity. Scott Deakin, 60, a former CFO of Gypsum Management & Supply, Inc., will serve as interim Executive Vice President and CFO from July 1 while the company searches for a permanent successor. The filing states that her departure is not related to the company's financial or operating results or to any disagreements over accounting or reporting.
Christina Zamarro steps down as EVP and CFO effective June 30, 2026, and leaves the company July 10, 2026.
Scott Deakin, 60, becomes interim EVP and CFO effective July 1, 2026, and will be the principal financial officer until a permanent CFO is appointed.
Deakin will receive a salary of $30,000 per week, a bonus of $5,000 per week based on weeks worked, and restricted stock units with a $500,000 grant date value.
Deakin was CFO of Gypsum Management & Supply, Inc. from 2019 to 2026; the company is conducting a comprehensive search for a permanent CFO.
H.B. Fuller and the board of Advanced Medical Solutions Group plc (AMS) agreed terms on a recommended cash offer, to be implemented through a UK court-sanctioned scheme of arrangement. The company has arranged bridge credit agreements of up to $2,086,713,188 (secured) and $917,000,000 (unsecured) to fund the deal and refinance debt, and expects completion by the end of calendar 2026, which would add new borrowings for shareholders to weigh against the strategic growth case.
AMS shareholders will receive 285 pence in cash per AMS share; the press release cites a total enterprise value of £715 million.
Secured Bridge Credit Agreement of up to $2,086,713,188 and Unsecured Bridge Credit Agreement of up to $917,000,000, both with Goldman Sachs Bank USA; loans would mature 364 days after closing.
Completion is expected by the end of calendar 2026, subject to AMS shareholder approval, High Court sanction, regulatory approvals, and a Long-Stop Date of June 25, 2027.
Company expects approximately $55 million in combined run-rate revenue and cost synergies by 2031.
Atara Biotherapeutics said its chief accounting officer, Yanina Grant-Huerta, will leave effective July 17, 2026. The board appointed Kevin G. Sarney, a consultant from Charles River CFO, Inc., as interim chief financial officer effective June 26, 2026, and he will also serve as principal accounting officer. The change in its top finance roles is notable for shareholders because it comes through a consulting arrangement rather than a permanent hire.
Yanina Grant-Huerta, Chief Accounting Officer, was notified June 22, 2026 that her employment ends effective July 17, 2026.
Kevin G. Sarney appointed interim chief financial officer effective June 26, 2026, serving as principal financial and principal accounting officer.
Sarney's services are provided under a consulting agreement with Charles River CFO, Inc.; the Company pays an agreed hourly rate and Sarney receives no direct compensation from the Company.
The consulting agreement can be terminated by either party on 30 days written notice.
Ark Restaurants said a New York court on June 18, 2026 granted it summary judgment on its breach of contract claim over the Bryant Park Grill lease and the related right of first lease for the Bryant Park Café, with money damages to be set at a later trial. The court also ruled against the company on ejectment and use and occupancy claims for the Café and The Porch, and the company says it will appeal the adverse portions, which would automatically stay eviction while the appeal is pending. The company says the dispute has had and is expected to continue to have a material adverse impact on its business and results.
June 18, 2026: court granted Ark summary judgment on breach of contract for the Bryant Park Grill lease and related right of first lease for the Bryant Park Café
Court did not grant specific performance and did not preclude the Landlord's ejectment claim; damages for the Grill to be determined at a future trial
Court ruled for the Landlord on ejectment, use and occupancy, and breach of contract for the Café and The Porch; the Landlord may seek use and occupancy damages at trial
Company intends to file a Notice of Appeal, which would stay eviction pending appeal; the court will set the amount of the required undertaking
REalloys Inc. closed a private placement on June 26, 2026, selling 7,017,540 shares of common stock at $14.25 per share for gross proceeds of approximately $100 million, before placement agent fees and offering expenses. The company will use the net proceeds for working capital and general corporate purposes, and it has agreed to register the resale of the shares, which adds new shares that could dilute existing shareholders.
Sold 7,017,540 shares of common stock at $14.25 per share, for gross proceeds of approximately $100 million
Closed on June 26, 2026, after the purchase agreement was signed on June 24, 2026
Clear Street LLC was the sole placement agent; net proceeds will go to working capital and general corporate purposes
Company agreed to file a registration statement to register the resale of the shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.